Abstract Details

Title Peripheral Blood Pro-inflammatory Cytokines Are Related to MRI Disease Activity in Multiple Sclerosis Patients

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 234

Objective

Background BACKGROUND: Multiple Sclerosis (MS) is characterized by a complex system of interactions between pro-inflammatory and anti-inflammatory cytokines in its course. Several pro-inflammatory cytokines have been proposed to play central roles in disease activity, but few data analyzed the relationships between such cytokines and MRI markers of the disease.

Design/Methods DESIGN/METHODS: Twenty-two patients with RRMS were evaluated. We assessed cell culture supernatants levels of IL-10, IL-6, TNF? and INF-? and serum levels of BDNF using ELISA. All patients underwent MRI in a 3T scanner, including FLAIR, double-inversion recovery (DIR), and T1 with gadolinium. Brain cortical lesions (CL) were segmented on DIR sequences, white-matter lesion volume (WML) in FLAIR sequences, and gadolinium-enhancing (Gd+) lesions in T1 using a semiautomatic thresholding technique (MIPAV software).

Results RESULTS: We included seven male and 15 female patients with RRMS treated with interferon-beta. Mean age was 28.9 years (±6.7) with 4.7 years (±4.8) of disease duration and median EDSS score of 2.5 (±1.0). Mean levels of cytokines were: INF-? 1800.7 pg/mL; TNF? 408.8 pg/mL; IL-10 2033.9 pg/mL; and IL-6 6963.0 pg/mL. Mean serum BDNF was 28.2 ng/mL. Patients with Gd+ lesions had superior levels of INF-?, TNF? and IL-6 (p=0.019, p=0.019, and p=0.038, respectively). Higher levels of INF-?, TNF? and IL-6 were also related with greater volume of Gd+ lesions (R=0.58, p=0.02; R=0.59, p=0.02; and R=0.53, p=0.03, respectively) but not with CLs or WMLs. IL-10 and BDNF were not related to these MRI metrics.

Conclusions CONCLUSIONS: Higher peripheral blood levels of INF-?, TNF? and IL-6 are related to active MRI lesions as measured by Gd+ lesions, but not with prior white-matter/cortical lesion burden. These pro-inflammatory cytokines may be used as alternative markers of disease activity in RRMS patients.

Authors/Disclosures
Alfredo Damasceno, MD PRESENTER	No disclosure on file
	No disclosure on file
Felipe Von Glehn Silva, MD, PhD, MSc, FAAN (University of Brasilia – School of Medicine)	Dr. Von Glehn Silva has nothing to disclose.
Juanzhi Fang (EMD Serono)	No disclosure on file
Benito P. Damasceno, MD, PhD (Neurology Department, Medical School, State University of Campinas (UNICAMP))	No disclosure on file
	No disclosure on file
Fernando Cendes, MD, PhD, FAAN (Departamento de Neurologia; FCM; UNICAMP)	Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Biopharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for United Medical – Brazil. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zodiac Pharma . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eurofarma – Brazil . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology - Epilepsy. The institution of Dr. Cendes has received research support from São Paulo Research Foundation - FAPESP. The institution of Dr. Cendes has received research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico - Brazil . The institution of Dr. Cendes has received research support from NIH.

��ɫ��

��ɫ��